

## **Radiopharm appoints Dr. Rama Abu Shmeis as Senior Vice President, Chemistry and Manufacturing Controls**

Sydney, Australia – 11 January 2023 – Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Dr. Rama Abu Shmeis as Senior Vice President (SVP), Chemistry, Manufacturing, and Controls (CMC).

Dr. Shmeis joins Radiopharm as a highly accomplished executive with 23 years of achievements in leading strategic, operational and scientific aspects of CMC development and manufacturing across all stages, from pre-clinical through all clinical stages to commercialization, covering a wide variety of dose forms, products and technologies.

Dr. Shmeis has demonstrated an outstanding record in building and leading highly functional teams of scientists and engineers, working toward aggressive timelines, managing external partners and Contract Development and Manufacturing Organizations (CDMOs) advancing 25+ new molecular entities on a speed to market timeline with an emphasis on science, innovation and quality. This led to successful global regulatory CMC submissions, approvals and market launches across multiple therapeutic areas including Oncology, Virology, Neuroscience and Pain Management.

She also headed CMC due diligence evaluations leading to several acquisitions, in-licensing, out-licensing and strategic alliances.

Most recently Dr. Shmeis held the role of Vice President, CMC & Manufacturing Operations at each of B-cell disease focused TG Therapeutics and immunotherapy developer Checkpoint Therapeutics, serving at these NASDAQ-listed companies for more than five years. Prior to that her experience includes tenures with Eagle Pharmaceuticals, Keryx Biopharmaceuticals, Purdue Pharma, Sanofi-Aventis, Boehringer-Ingelheim Pharmaceuticals and Novartis Pharmaceutical Corporation.

Dr. Shmeis holds a Ph.D. in Pharmaceutics and a Bachelor of Science in Pharmacy and has a record of invited presentations at national and international conferences, publications in peer-reviewed journals as well as several patents.

Radiopharm's Chief Executive Officer & Managing Director, Riccardo Canevari, said: "We're obviously thrilled to add another excellent senior team member with top shelf experience in the USA market."

"Dr. Shmeis is known for developing creative solutions to complex problems in the sector, in addition to a strong ability to anticipate risk and therefore establish appropriate strategies to manage this. With a big picture focus and high-level attention to detail, we're looking forward to her contribution to our vision at Radiopharm."

**Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.**

**For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: [rc@radiopharmtheranostics.com](mailto:rc@radiopharmtheranostics.com)

**ASX ANNOUNCEMENT  
11 JANUARY 2023**



Paul Hopper  
Executive Chairman  
P: +61 406 671 515  
E: paulhopper@lifescienceportfolio.com

Matt Wright  
NWR Communications  
P: +61 451 896 420  
E: matt@nwrcommunications.com.au

**Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>